GSK Plans $800M-Plus Biologics Campus Expansion in Upper Merion, Pennsylvania
GSK will expand its biopharmaceutical manufacturing campus in Upper Merion Township, Pa., spending more than $800 million on new biologics manufacturing, research and lab buildings. Construction is set to begin in 2027, with operations targeted for 2030. Combined with its separate Marietta project, GSK's Pennsylvania commitments approach $1.7 billion.
Our summary of an article from ENR (Engineering News-Record). Read the original at ENR (Engineering News-Record)
What It Means
A 2027 start and a 2030 operating target leave a fairly short window for a brownfield biologics project that includes demolition on an active campus. Teams will need to run design, phased construction and qualification planning in parallel so existing operations keep going. Programs like this often succeed or fail on how early commissioning and validation strategy gets locked in.
Read the original at ENR (Engineering News-Record).
